Titan implanting treatments for opioid dependence
In the continuing struggle to circumvent abuse of drugs to treat opioid dependence and enhance compliance regimes for better outcomes, Titan Pharmaceuticals (OTCBB:TTNP) is leading the race with a...
View ArticleTitan Pharma Phase 3 data validate ProNeura technology
Titan Pharmaceuticals’ (OTCQB:TTNP) positive topline results from a Phase 3 clinical study of Probuphine, its subdermal implant of buprenorphine for the long-term maintenance treatment of opioid...
View ArticleTitan presents nonclinical ProNeura data in Parkinson’s
Titan Pharmaceuticals (OTCQB:TTNP) has presented nonclinical data at the 19th International Congress of Parkinson’s Disease and Movement Disorders in San Diego, demonstrating the potential of Titan’s...
View ArticleTitan Pharma advancing pipeline in PD, other disorders
Titan Pharmaceuticals (NASDAQ:TTNP), which is awaiting an FDA approval decision for its six-month Probuphine implant to treat opioid dependence, is advancing its ProNeura implant technology against...
View ArticleTitan adds ProNeura implant for hypothyroidism to pipeline
Titan Pharmaceuticals (NASDAQ:TTNP) has added an implantable triiodothyronine (T3) product for the treatment of hypothyroidism to its product development pipeline. Hypothyroidism affects about 15...
View ArticleRoth ups Titan Pharma price target to $7.25
Roth Capital Partners has raised its price target on “buy-rated” Titan Pharmaceuticals (NASDAQ:TTNP) to $7.25 from $6.50 to reflect an increased value attributed to Titan’s pipeline. The stock closed...
View Article
More Pages to Explore .....